Trial Profile
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 May 2021
Price :
$35
*
At a glance
- Drugs Ofranergene obadenovec (Primary) ; Bevacizumab
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Sponsors VBL Therapeutics
- 08 Jan 2020 According to a VBL Therapeutics media release, data from this trial were published in the peer-reviewed journal Neuro-Oncology.
- 08 Jan 2020 Results presented in the VBL Therapeutics Media Release.
- 04 Jun 2019 Results assessing quantitative radiographic results and impact on OS from NCT01260506 and NCT02511405 trials presented at the 55th Annual Meeting of the American Society of Clinical Oncology